Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Metastatic × Cyclophosphamide × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 83 Carcinoma, Ovarian Epithelial 28 Fallopian Tube Neoplasms 23 Breast Neoplasms 23 Carcinoma, Non-Small-Cell Lung 19 Melanoma 18 Uterine Cervical Neoplasms 15 Pancreatic Neoplasms 13 Colorectal Neoplasms 12 Neoplasm Metastasis 11 Stomach Neoplasms 10 Sarcoma 9 Carcinoma, Hepatocellular 9 Neoplasms 8 Lung Neoplasms 8 Head and Neck Neoplasms 8 Triple Negative Breast Neoplasms 7 Recurrence 7 Multiple Myeloma 7 Esophageal Neoplasms 7 Anus Neoplasms 7 Neuroblastoma 6 Urinary Bladder Neoplasms 5 Testicular Neoplasms 5 Lymphoma, Non-Hodgkin 5 Lymphoma, Follicular 5 Lymphoma 5 Endometrial Neoplasms 5 Colonic Neoplasms 5 Carcinoma, Renal Cell 5

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡